Drug intelligence / Profile preview

NV101

Development stage: Preclinical
Lead developer: NanoValent Pharmaceuticals
Modality: Nanoparticles → Drug Delivery Systems

Overview

NV101 is a drug candidate developed by NanoValent Pharmaceuticals, utilizing its proprietary Targeted Nanospheres (TNS)/Hybrid Polymerized Liposomal Nanoparticle (HPLN) technology. It is being developed for the treatment of pediatric cancers, including Ewing Sarcoma.

Targets

CD99 (CD99 molecule)

Beyond the preview

Go deeper on NV101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NV101.

Explore the full profile